Real-World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated With Inotuzumab Ozogamicin.
Allogeneic HCT
B-cell ALL
Ph-positive ALL
RR ALL
VOD
Journal
Clinical lymphoma, myeloma & leukemia
ISSN: 2152-2669
Titre abrégé: Clin Lymphoma Myeloma Leuk
Pays: United States
ID NLM: 101525386
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
02
02
2020
revised:
04
03
2020
accepted:
12
03
2020
pubmed:
16
4
2020
medline:
21
8
2021
entrez:
16
4
2020
Statut:
ppublish
Résumé
Inotuzumab ozogamicin (InO) is an anti-CD22 monoclonal antibody-drug (calicheamicin) conjugate that has shown superior efficacy compared to conventional chemotherapy in relapsed/refractory (RR) B-cell acute lymphocytic leukemia (ALL) patients. We sought to find the safety and efficacy of InO in a real-world setting. A multicenter cohort analysis on 84 RR ALL patients who received InO outside of clinical trials was conducted to evaluate response and toxicity. The median (range) age of patients at InO initiation was 50 (20-87) years. Forty patients (48%) had ≥ 3 therapies and 23 patients (27%) underwent allogeneic hematopoietic stem-cell transplantation (allo-HCT) before InO. The median (range) number of cycles of InO provided was 2 (1-6), and cumulative dose was 3.3 (1.8-9.3) mg/m InO was well tolerated and had significant efficacy in RR B-cell ALL patients.
Sections du résumé
BACKGROUND
Inotuzumab ozogamicin (InO) is an anti-CD22 monoclonal antibody-drug (calicheamicin) conjugate that has shown superior efficacy compared to conventional chemotherapy in relapsed/refractory (RR) B-cell acute lymphocytic leukemia (ALL) patients. We sought to find the safety and efficacy of InO in a real-world setting.
PATIENTS AND METHODS
A multicenter cohort analysis on 84 RR ALL patients who received InO outside of clinical trials was conducted to evaluate response and toxicity.
RESULTS
The median (range) age of patients at InO initiation was 50 (20-87) years. Forty patients (48%) had ≥ 3 therapies and 23 patients (27%) underwent allogeneic hematopoietic stem-cell transplantation (allo-HCT) before InO. The median (range) number of cycles of InO provided was 2 (1-6), and cumulative dose was 3.3 (1.8-9.3) mg/m
CONCLUSION
InO was well tolerated and had significant efficacy in RR B-cell ALL patients.
Identifiants
pubmed: 32291234
pii: S2152-2650(20)30137-3
doi: 10.1016/j.clml.2020.03.004
pii:
doi:
Substances chimiques
Antineoplastic Agents, Immunological
0
Inotuzumab Ozogamicin
P93RUU11P7
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
556-560.e2Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.